Though clinical trial data support the efficacy of dual GIPR/GLP1R agonism for glycemic control in type 2 diabetes, it is unclear whether pharmacological GIPR agonism alone would confer similar favorable effects on glucose metabolism.36 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.